Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGX) have been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $16.67.

MGX has been the topic of a number of recent research reports. Chardan Capital reissued a “buy” rating and set a $15.00 price target on shares of Metagenomi in a research report on Wednesday, November 20th. HC Wainwright raised their target price on shares of Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, December 10th.

Metagenomi Trading Down 2.0 %

Shares of NASDAQ MGX opened at $2.97 on Friday. Metagenomi has a 52-week low of $1.61 and a 52-week high of $12.74. The stock has a 50 day moving average price of $2.90 and a 200 day moving average price of $2.92.

Institutional Investors Weigh In On Metagenomi

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in Metagenomi by 105.8% in the third quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after acquiring an additional 173,796 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Metagenomi by 209.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after purchasing an additional 92,468 shares in the last quarter. Fortitude Advisory Group L.L.C. purchased a new stake in Metagenomi during the 4th quarter worth approximately $273,000. Novo Holdings A S increased its stake in Metagenomi by 3.5% during the 2nd quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock valued at $7,344,000 after purchasing an additional 60,825 shares in the last quarter. Finally, Marquette Asset Management LLC acquired a new stake in shares of Metagenomi during the fourth quarter worth $184,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.